Related references
Note: Only part of the references are listed.
Article
Infectious Diseases
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
Bihua Han et al.
Summary: The study evaluated the safety, tolerability, and immunogenicity of the candidate COVID-19 vaccine CoronaVac containing inactivated SARS-CoV-2 in children and adolescents aged 3-17 years. The research findings indicate that the 3.0 μg dose induced higher levels of neutralizing antibodies compared to the 1.5 μg dose, supporting the use of the 3.0 μg dose for further studies in this age group.
LANCET INFECTIOUS DISEASES (2021)
Share Paper
